Exencial Wealth Advisors LLC Has $11.86 Million Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• Exencial Wealth Advisors LLC reduced its holdings in Becton, Dickinson and Company by 2.9%, totaling $11.86 million worth of stock at the end of the second quarter.
• Several major hedge funds, including Vanguard Group and T. Rowe Price, have increased their stakes in Becton, Dickinson and Company, indicating strong institutional interest.
• Analysts have varied opinions on the stock, with a consensus rating of "Hold" and an average target price of $205.40, reflecting cautious optimism among investment analysts.

Exencial Wealth Advisors LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,877 shares of the medical instruments supplier's stock after selling 2,046 shares during the period. Exencial Wealth Advisors LLC's holdings in Becton, Dickinson and Company were worth $11,864,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock worth $2,880,510,000 after purchasing an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after purchasing an additional 667,957 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after purchasing an additional 312,124 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Becton, Dickinson and Company by 0.4% in the 2nd quarter. Nordea Investment Management AB now owns 3,365,509 shares of the medical instruments supplier's stock worth $577,420,000 after purchasing an additional 12,602 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Piper Sandler restated a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Finally, Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and an average target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $188.97 on Wednesday. The firm has a market capitalization of $54.16 billion, a PE ratio of 33.99, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. The firm has a fifty day simple moving average of $190.46 and a two-hundred day simple moving average of $184.29. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 1,838 shares of company stock worth $348,392. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.